| dc.contributor |
Universitat de Vic - Universitat Central de Catalunya. Càtedra de la Sida i Malalties Relacionades |
| dc.contributor.author |
Gómez, Carmen E. |
| dc.contributor.author |
Perdiguero, Beatriz |
| dc.contributor.author |
García Arriaza, Juan |
| dc.contributor.author |
Cepeda, Victoria |
| dc.contributor.author |
Sánchez-Sorzano, Carlos Óscar |
| dc.contributor.author |
Mothe, B. |
| dc.contributor.author |
Jiménez, José Luis |
| dc.contributor.author |
Muñoz Fernández, María Ángeles |
| dc.contributor.author |
Gatell, J.M. |
| dc.contributor.author |
López Bernaldo de Quirós, Juan Carlos |
| dc.contributor.author |
Brander, Christian |
| dc.contributor.author |
Garcia, Felipe |
| dc.contributor.author |
Esteban, Mariano |
| dc.date |
2015 |
| dc.identifier |
Elena Gomez, C., Perdiguero, B., Garcia-Arriaza, J., Cepeda, V., Oscar Sanchez-Sorzano, C., Mothe, B., et al. (2015). A phase I randomized therapeutic MVA-B vaccination improves the magnitude and quality of the T cell immune responses in HIV-1-infected subjects on HAART. PLoS One, 10(11), e0141456 |
| dc.identifier |
1932-6203 |
| dc.identifier |
http://hdl.handle.net/10854/4418 |
| dc.identifier |
https://doi.org/10.1371/journal.pone.0141456 |
| dc.identifier.uri |
http://hdl.handle.net/10854/4418 |
| dc.description |
Trial Design
Previous studies suggested that poxvirus-based vaccines might be instrumental in the therapeutic
HIV field. A phase I clinical trial was conducted in HIV-1-infected patients on highly
active antiretroviral therapy (HAART), with CD4 T cell counts above 450 cells/mm3 and
undetectable viremia. Thirty participants were randomized (2:1) to receive either 3 intramuscular
injections of MVA-B vaccine (coding for clade B HIV-1 Env, Gag, Pol and Nef antigens)
or placebo, followed by interruption of HAART.
Methods
The magnitude, breadth, quality and phenotype of the HIV-1-specific T cell response were
assayed by intracellular cytokine staining (ICS) in 22 volunteers pre- and post-vaccination.
Results
MVA-B vaccine induced newly detected HIV-1-specific CD4 T cell responses and expanded
pre-existing responses (mostly against Gag, Pol and Nef antigens) that were high in magnitude,
broadly directed and showed an enhanced polyfunctionality with a T effector memory
(TEM) phenotype, while maintaining the magnitude and quality of the pre-existing HIV-1-
specific CD8 T cell responses. In addition, vaccination also triggered preferential CD8+ T
cell polyfunctional responses to the MVA vector antigens that increase in magnitude after
two and three booster doses. |
| dc.format |
application/pdf |
| dc.language |
eng |
| dc.publisher |
Plos One |
| dc.rights |
Aquest document està subjecte a aquesta llicència Creative Commons |
| dc.rights |
http://creativecommons.org/licenses/by/3.0/es/ |
| dc.rights |
info:eu-repo/semantics/openAccess |
| dc.subject |
Sida -- Tractament |
| dc.subject |
VIH (Virus) |
| dc.title |
A phase I randomized therapeutic MVA-B vaccination improves the magnitude and quality of the T cell immune responses in HIV-1-infected subjects on HAART |
| dc.type |
info:eu-repo/semantics/article |
| dc.type |
info:eu-repo/publishedVersion |
